Am J Transplant, Volume 18, Suppl 3 Archives - Page 57 of 211 - ATC Abstracts

2018 American Transplant Congress
Variation in Cost of Death and Graft Failure across All Solid Organs
M. Schnitzler,^1,2 M. Skeans,² D. Axelrod,³ K. Lentine,¹ H. Randall.¹
¹St. Louis Univ, St. Louis, MO; ²SRTR, Minneapolis, MN; ³Lahey Hosp & Med Ctr, Burlington, VT.
Medicare costs for transplant vary considerably by organ, and costs in the second posttransplant year (Y2) are lower than in the first (Y1). Variability in…
2018 American Transplant Congress
Lymphatic Endothelium Requires S1PR2 for T Cell Transendothelial Migration
Y. Xiong,¹ W. Piao,¹ C. Brinkman,¹ L. Li,¹ J. Kulinski,² A. Olivera,² A. Cartier,³ T. Hla,³ S. Schwab,⁴ K. Hippen,⁵ B. Blazar,⁵ J. Bromberg.¹
¹UMB, MD; ²NIH, MD; ³Boston Children's Hospital, MA; ⁴NYU, NY; ⁵U. Minnesota, MN.
Introduction: Sphingosine 1-phosphate (S1P) receptors 1 (S1PR1) and S1PR2 are highly expressed by lymphatic endothelial cells (LEC), while T cells express S1PR1 and S1PR4. S1P…
2018 American Transplant Congress
Ex Vivo Expanded Regulatory T Cells Combined with Short-Term Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts
B. Oh,¹ G. Furtmüller,¹ M. Grzelak,¹ L. Vuong,² M. Iglesias,¹ M. Fryer,¹ D. Cooney,¹ W. Lee,¹ G. Raimondi,¹ G. Brandacher.¹
¹Plastic and Reconstructive Surgery, Johns Hopkins SOM, Baltimore; ²Washington University in St. Louis SOM, St. Louis.
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…
2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
P. Malvezzi,¹ S. Bunnapradist,² D. Stevens,³ M. Moten,³ A. Loh,³ S. Patel,³ L. Rostaing.¹
¹Service De Néphrologie, Hémodialyse, Aphérèses Et Transplantation Rénale, Chu Grenoble Alpes, La Tronche, France; ²Nephrology, University of California, Los Angeles, Los Angeles, CA; ³Veloxis, Cary, NC.
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…
2018 American Transplant Congress
Predictive Scores for Delayed Graft Function Based on Hypothermic Machine Perfusion Variables in Kidney Transplantation
C. Ding,^1,2 W. Xue,^1,2 P. Tian,^1,2 X. Ding,^1,2 X. Pan,^1,2 H. Xiang,^1,2 Y. Li,^1,2 X. Tian,^1,2 F. Han,^1,2 Q. Tai.^1,2
¹Department of Kidney Transplantation, Nephropathy Hospital, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; ²Institute of Organ Transplantation, Xi'an Jiaotong University, Xi'an, China.
Background Hypothermic machine perfusion (HMP) is increasingly being used in cardiac death kidney transplantation, but the value of assessing organ quality and predicting DGF through…
2018 American Transplant Congress
Living Donor Liver Transplantation for Alcoholic Liver Disease: Data from the A2ALL Study
H. Braun, J. Dodge, J. Grab, S. Syed, G. Roll, C. Freise, J. Roberts, N. Ascher.
Surgery, University of California, San Francisco, San Francisco, CA.
The literature on living donor liver transplantation (LDLT) for alcoholic liver disease (ALD) is primarily from single Asian centers. We investigated LDLT outcomes for ALD…
2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
A. Kwong,¹ A. Wall,² M. Melcher,² U. Wang,³ A. Ahmed,¹ K. Khush,³ A. Subramanian,³ J. Tan,³ P. Kwo.¹
¹Gastroenterology and Hepatology, Stanford University, Palo Alto, CA; ²Surgery, Stanford University, Palo Alto, CA; ³Stanford University, Palo Alto, CA.
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…
2018 American Transplant Congress
Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients
J. Leventhal,¹ J. Galvin,¹ J. Mathew,¹ L. Gallon,¹ D. Stare,¹ K. Kurtenbach,¹ K. Ravindra,³ M. Horwitz,³ J. Miller,¹ M. Abecassis,¹ S. Ildstad.²
¹Surgery, Northwestern U, Chicago; ²U of Louisville, Louisville; ³Duke U, Durham.
37 pts have been transplanted in a phase 2 protocol to induce tolerance in recipients of living donor renal allografts (KTx). The protocol is based…
2018 American Transplant Congress
Superior Renal Function with CNI-Free Everolimus over Standard CNI-Based Regimen: 18 Months Data from the Randomized, Multi-Center MANDELA Trial in De Novo Heart Transplant Recipients
M. J. Barten,¹ S. W. Hirt,¹ J. Garbade,¹ C. Bara,¹ A. Doesch,¹ C. Knosalla,¹ C. Grinninger,¹ J. Stypmann,¹ C. Sieder,² M. Junge,² U. Schulz.¹
¹Mandela Study Group, Germany; ²Novartis, Pharma, Germany.
Purpose: The MANDELA study (NCT00862979) was designed to assess the benefit on renal function of either CNI-free or CNI-minimized EVR-based regimen after early conversion of…
2018 American Transplant Congress
Elucidating Novel Signatures of Allograft Rejection through Cytometry by Time of Flight (CyTOF) in Kidney Transplant Recipients
S. Eskandari,¹ B. Al Dulaijan,¹ J. Assaker,¹ L. Riella,¹ A. Kurdi,² J. Azzi.¹
¹Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Mass cytometry by time-of-flight (CyTOF) permits the simultaneous assessment of over 40 functional and phenotypic parameters at the single-cell level. This novel tool holds tremendous…